Petmed Express Inc launches new health product collection
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 10 2025
0mins
Source: Globenewswire
Petmed Express Inc saw a significant price increase of 11.30%, breaking above the 20-day SMA. This surge is attributed to the company's launch of its 2025 Holiday Health Product Collection, which focuses on innovative health and lifestyle products for pets.
The new collection includes emergency kits and DNA tests, reflecting a growing trend among pet owners who prioritize their pets' health and well-being. This product innovation is expected to drive sales growth and enhance brand loyalty, positioning Petmed Express Inc favorably in the competitive pet health market.
As the demand for health-oriented pet products rises, Petmed Express Inc's strategic move to diversify its offerings could lead to increased market share and customer satisfaction, further solidifying its leadership in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PETS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PETS
About PETS
PetMed Express, Inc., doing business as PetMeds, is a direct-to-consumer pet pharmacy. The Company is an online provider of prescription and non-prescription medications, food, supplements, and supplies and has veterinary and pet insurance service partnerships for dogs, cats, and horses. It markets and sells directly to consumers through their Websites, toll-free numbers, and employer benefit partnerships. Its product line contains over 15,000 SKUs of pet medications, health products, foods, and supplies. The Company offers various pet supplies, including beds, crates, stairs and other pet supplies. Its products include Prescription Medications (Rx), Non-Prescription Medications (OTC) and supplies, Pet Foods, Private Label and Holistic Wellness Services. Rx includes heartworm and flea and ticks preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PetMed Express Receives Acquisition Proposal from SilverCape
- Acquisition Proposal Confirmation: PetMed Express's Board confirmed receipt of an unsolicited proposal from SilverCape Investments to acquire all outstanding shares at $3.00 per share in cash, following a previous offer of $4.00 per share in December 2025, indicating ongoing interest from the acquirer.
- Board Evaluation Process: The Board, with the assistance of financial and legal advisors, will carefully evaluate the proposal to determine the best course of action for the Company and all shareholders, demonstrating the company's commitment to shareholder value.
- Diligence Materials Prepared: Although the Company prepared extensive diligence materials and a formal management presentation for SilverCape, the acquirer ultimately declined to sign a nondisclosure agreement with a standard standstill provision, reflecting the complexities involved in the acquisition negotiations.
- Uncertainty of Future Transactions: The Board has not reached any determination regarding SilverCape's latest proposal and cannot assure that any transaction will result, indicating the Company's cautious approach in acquisition discussions while remaining focused on core operations and maximizing long-term shareholder value.
See More
SilverCape Revises Acquisition Proposal for PetMed Express
- Revised Acquisition Proposal: Singapore-based SilverCape Investments has proposed to acquire all outstanding shares of PetMed Express for $3.00 per share in cash, reflecting the company's ongoing deterioration and aiming to provide shareholders with a superior alternative to the current value-destructive trajectory.
- Value Warning: In an open letter, SilverCape warned that PetMed is no longer viable as a public company due to dismal quarterly and fiscal reports, rapidly depleting cash reserves, and ineffective leadership, urging the Board to act swiftly to prevent further erosion of the company's remaining value.
- Positive Market Reaction: In pre-market trading, PetMed's stock rose by 32.43% to $2.3399, indicating a positive market response to SilverCape's acquisition proposal, although the current price remains below the proposed offer.
- Support for Independent Evaluation: SilverCape expressed openness to other third-party alternatives that offer superior value and supports PetMed in conducting a structured and independent process to consider these alternatives, demonstrating a commitment to the company's future and shareholder interests.
See More
NASDAQ 100 Pre-Market Indicator Rises Significantly
- Market Indicator Surge: The NASDAQ 100 Pre-Market Indicator increased by 244.55 points to 29,362.79, indicating a positive shift in market sentiment that may attract more investor interest in tech stocks.
- Active Stock Performance: NN, Inc. (NNBR) rose by $1.31 to $4.07 with a trading volume of 39,045,126 shares, currently at 67.83% of its target price, reflecting market confidence in its future performance.
- Other Stock Movements: Comcast Corporation (CMCSA) increased by $5.38 to $28.55 with 7,275,313 shares traded, currently at 89.22% of its target price, suggesting optimistic expectations from investors regarding its growth potential.
- Bitcoin ETF Performance: iShares Bitcoin Trust ETF (IBIT) gained $0.35 to $34.20, representing a 4.14% increase from its 52-week low, highlighting ongoing market interest and investment enthusiasm in cryptocurrencies.
See More
SilverCape Revises Acquisition Proposal for PetMed Express
- Proposal Revision: SilverCape Investments announced on Monday that it has revised its proposal to acquire all outstanding shares of PetMed Express (PETS), lowering its cash offer from $4 per share made in December 2025 to $3 per share, reflecting the company's deteriorating financial condition.
- Shareholder Premium: Despite the reduced offer, SilverCape claims the new proposal still represents a roughly 70% premium over PetMed's closing price of $1.76 on June 26, aiming to provide shareholders with immediate liquidity amid current financial challenges.
- Deteriorating Business: SilverCape highlighted that PetMed's business has continued to weaken since the original proposal, citing declining prescription medication revenue, falling repeat customer sales, rising customer acquisition costs, negative adjusted EBITDA, and a drop in cash from $54.7 million to $21.4 million over the past fiscal year.
- Governance Concerns: SilverCape raised concerns about PetMed's leadership and governance, noting high executive turnover, low insider ownership, and the board's handling of previous acquisition proposals, urging the board to engage with its proposal or conduct a bona fide sale process.
See More
SilverCape Urges PetMed Board to Act on Acquisition Proposal
- Destruction of Shareholder Value: SilverCape Investments highlights that PetMed's stock plummeted from $32.30 on July 2, 2021, to $1.76 on June 26, 2026, indicating severe governance failures and a lack of strategic direction that has eroded shareholder value.
- Acquisition Proposal: SilverCape proposes to acquire PetMed for $3.00 per share in cash, representing a 70% premium over the current stock price, aiming to provide immediate liquidity to shareholders and prevent further erosion of the company's value.
- Leadership Instability: PetMed has seen two CEOs and CFOs depart in the past two years, with current Chair and Interim CEO Leslie C.G. Campbell's leadership being questioned, resulting in a lack of effective strategic direction for the company.
- Governance Failures: The board members own only 2% of the company’s shares, showing a lack of accountability to shareholders, and the company has failed to file financial reports on time, exacerbating shareholder concerns about its future.
See More
SilverCape Urges PetMed Board to Act on Acquisition Proposal
- Destruction of Shareholder Value: SilverCape Investments highlights that PetMed's stock price plummeted from $32.30 on July 2, 2021, to $1.76 on June 26, 2026, indicating severe mismanagement and strategic failures that have led to significant shareholder value erosion.
- Acquisition Proposal: SilverCape has proposed to acquire all outstanding shares of PetMed for $3.00 per share in cash, representing approximately a 70% premium over the current stock price, aimed at providing immediate liquidity to shareholders and preventing further value loss.
- Leadership Instability: PetMed has seen the departure of two CEOs and CFOs in just two years, with Chair and Interim CEO Leslie C.G. Campbell receiving a $1.3 million salary, which starkly contrasts with the company's sub-$40 million market capitalization, severely undermining investor confidence.
- Governance Failures: The board members own only 2% of PetMed's shares, demonstrating a lack of accountability to shareholders, while ineffective governance structures leave shareholders with almost no means to hold directors accountable, exacerbating the ongoing decline in company value.
See More
PetMed Express Receives Acquisition Proposal from SilverCape
- Acquisition Proposal Confirmation: PetMed Express's Board confirmed receipt of an unsolicited proposal from SilverCape Investments to acquire all outstanding shares at $3.00 per share in cash, following a previous offer of $4.00 per share in December 2025, indicating ongoing interest from the acquirer.
- Board Evaluation Process: The Board, with the assistance of financial and legal advisors, will carefully evaluate the proposal to determine the best course of action for the Company and all shareholders, demonstrating the company's commitment to shareholder value.
- Diligence Materials Prepared: Although the Company prepared extensive diligence materials and a formal management presentation for SilverCape, the acquirer ultimately declined to sign a nondisclosure agreement with a standard standstill provision, reflecting the complexities involved in the acquisition negotiations.
- Uncertainty of Future Transactions: The Board has not reached any determination regarding SilverCape's latest proposal and cannot assure that any transaction will result, indicating the Company's cautious approach in acquisition discussions while remaining focused on core operations and maximizing long-term shareholder value.
See More
SilverCape Revises Acquisition Proposal for PetMed Express
- Revised Acquisition Proposal: Singapore-based SilverCape Investments has proposed to acquire all outstanding shares of PetMed Express for $3.00 per share in cash, reflecting the company's ongoing deterioration and aiming to provide shareholders with a superior alternative to the current value-destructive trajectory.
- Value Warning: In an open letter, SilverCape warned that PetMed is no longer viable as a public company due to dismal quarterly and fiscal reports, rapidly depleting cash reserves, and ineffective leadership, urging the Board to act swiftly to prevent further erosion of the company's remaining value.
- Positive Market Reaction: In pre-market trading, PetMed's stock rose by 32.43% to $2.3399, indicating a positive market response to SilverCape's acquisition proposal, although the current price remains below the proposed offer.
- Support for Independent Evaluation: SilverCape expressed openness to other third-party alternatives that offer superior value and supports PetMed in conducting a structured and independent process to consider these alternatives, demonstrating a commitment to the company's future and shareholder interests.
See More
NASDAQ 100 Pre-Market Indicator Rises Significantly
- Market Indicator Surge: The NASDAQ 100 Pre-Market Indicator increased by 244.55 points to 29,362.79, indicating a positive shift in market sentiment that may attract more investor interest in tech stocks.
- Active Stock Performance: NN, Inc. (NNBR) rose by $1.31 to $4.07 with a trading volume of 39,045,126 shares, currently at 67.83% of its target price, reflecting market confidence in its future performance.
- Other Stock Movements: Comcast Corporation (CMCSA) increased by $5.38 to $28.55 with 7,275,313 shares traded, currently at 89.22% of its target price, suggesting optimistic expectations from investors regarding its growth potential.
- Bitcoin ETF Performance: iShares Bitcoin Trust ETF (IBIT) gained $0.35 to $34.20, representing a 4.14% increase from its 52-week low, highlighting ongoing market interest and investment enthusiasm in cryptocurrencies.
See More
SilverCape Revises Acquisition Proposal for PetMed Express
- Proposal Revision: SilverCape Investments announced on Monday that it has revised its proposal to acquire all outstanding shares of PetMed Express (PETS), lowering its cash offer from $4 per share made in December 2025 to $3 per share, reflecting the company's deteriorating financial condition.
- Shareholder Premium: Despite the reduced offer, SilverCape claims the new proposal still represents a roughly 70% premium over PetMed's closing price of $1.76 on June 26, aiming to provide shareholders with immediate liquidity amid current financial challenges.
- Deteriorating Business: SilverCape highlighted that PetMed's business has continued to weaken since the original proposal, citing declining prescription medication revenue, falling repeat customer sales, rising customer acquisition costs, negative adjusted EBITDA, and a drop in cash from $54.7 million to $21.4 million over the past fiscal year.
- Governance Concerns: SilverCape raised concerns about PetMed's leadership and governance, noting high executive turnover, low insider ownership, and the board's handling of previous acquisition proposals, urging the board to engage with its proposal or conduct a bona fide sale process.
See More
SilverCape Urges PetMed Board to Act on Acquisition Proposal
- Destruction of Shareholder Value: SilverCape Investments highlights that PetMed's stock plummeted from $32.30 on July 2, 2021, to $1.76 on June 26, 2026, indicating severe governance failures and a lack of strategic direction that has eroded shareholder value.
- Acquisition Proposal: SilverCape proposes to acquire PetMed for $3.00 per share in cash, representing a 70% premium over the current stock price, aiming to provide immediate liquidity to shareholders and prevent further erosion of the company's value.
- Leadership Instability: PetMed has seen two CEOs and CFOs depart in the past two years, with current Chair and Interim CEO Leslie C.G. Campbell's leadership being questioned, resulting in a lack of effective strategic direction for the company.
- Governance Failures: The board members own only 2% of the company’s shares, showing a lack of accountability to shareholders, and the company has failed to file financial reports on time, exacerbating shareholder concerns about its future.
See More
SilverCape Urges PetMed Board to Act on Acquisition Proposal
- Destruction of Shareholder Value: SilverCape Investments highlights that PetMed's stock price plummeted from $32.30 on July 2, 2021, to $1.76 on June 26, 2026, indicating severe mismanagement and strategic failures that have led to significant shareholder value erosion.
- Acquisition Proposal: SilverCape has proposed to acquire all outstanding shares of PetMed for $3.00 per share in cash, representing approximately a 70% premium over the current stock price, aimed at providing immediate liquidity to shareholders and preventing further value loss.
- Leadership Instability: PetMed has seen the departure of two CEOs and CFOs in just two years, with Chair and Interim CEO Leslie C.G. Campbell receiving a $1.3 million salary, which starkly contrasts with the company's sub-$40 million market capitalization, severely undermining investor confidence.
- Governance Failures: The board members own only 2% of PetMed's shares, demonstrating a lack of accountability to shareholders, while ineffective governance structures leave shareholders with almost no means to hold directors accountable, exacerbating the ongoing decline in company value.
See More
